These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34207315)

  • 1. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
    Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
    EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
    Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
    Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
    Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
    Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
    Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.
    Malhab LJ; Descamps S; Delaval B; Xirodimas DP
    Sci Rep; 2016 Nov; 6():37775. PubMed ID: 27901050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
    Picco G; Petti C; Sassi F; Grillone K; Migliardi G; Rossi T; Isella C; Di Nicolantonio F; Sarotto I; Sapino A; Bardelli A; Trusolino L; Bertotti A; Medico E
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27771609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis.
    Wu MH; Lee CY; Huang TJ; Huang KY; Tang CH; Liu SH; Kuo KL; Kuan FC; Lin WC; Shi CS
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Protein Neddylation for Cancer Therapy.
    Zhou L; Jia L
    Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
    Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
    Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
    EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
    Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
    Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
    Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Thiruvengadam SK; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
    Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
    Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
    Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
    Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
    Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neddylation-Independent Activities of MLN4924.
    Mao H; Sun Y
    Adv Exp Med Biol; 2020; 1217():363-372. PubMed ID: 31898238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.